MA48625A - Composés et méthodes de traitement de la douleur viscérale - Google Patents
Composés et méthodes de traitement de la douleur viscéraleInfo
- Publication number
- MA48625A MA48625A MA048625A MA48625A MA48625A MA 48625 A MA48625 A MA 48625A MA 048625 A MA048625 A MA 048625A MA 48625 A MA48625 A MA 48625A MA 48625 A MA48625 A MA 48625A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- visceral pain
- pain treatment
- treatment compounds
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 208000009935 visceral pain Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762503280P | 2017-05-08 | 2017-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA48625A true MA48625A (fr) | 2020-03-18 |
Family
ID=62245468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA048625A MA48625A (fr) | 2017-05-08 | 2018-05-08 | Composés et méthodes de traitement de la douleur viscérale |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20200078358A1 (enExample) |
| EP (1) | EP3621619B1 (enExample) |
| JP (1) | JP7247106B2 (enExample) |
| KR (1) | KR20200005614A (enExample) |
| CN (1) | CN110709085A (enExample) |
| AU (1) | AU2018266145A1 (enExample) |
| BR (1) | BR112019023214A2 (enExample) |
| CA (1) | CA3062824A1 (enExample) |
| EA (1) | EA201992638A1 (enExample) |
| ES (1) | ES2956059T3 (enExample) |
| MA (1) | MA48625A (enExample) |
| MX (2) | MX2019013311A (enExample) |
| WO (1) | WO2018208848A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019013311A (es) | 2017-05-08 | 2020-08-03 | Arena Pharm Inc | Compuestos y metodos para el tratamiento del dolor visceral. |
| WO2023059610A1 (en) * | 2021-10-05 | 2023-04-13 | Arena Pharmaceuticals, Inc. | Crystalline forms and processes for the preparation of cannabinoid receptor modulators |
| WO2023150648A2 (en) * | 2022-02-02 | 2023-08-10 | Makscientific, Llc | Pharmaceutical compositions, and preparation and methods of use thereof |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5605906A (en) | 1995-03-24 | 1997-02-25 | Merck Frosst Canada, Inc. | Cannabinoid receptor agonists |
| JP3964478B2 (ja) | 1995-06-30 | 2007-08-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬 |
| US5971080A (en) | 1997-11-26 | 1999-10-26 | Central Sprinkler Corporation | Quick response dry pipe sprinkler system |
| US7308894B2 (en) | 1998-06-03 | 2007-12-18 | Scott Laboratories, Inc. | Apparatuses and methods for providing a conscious patient relief from pain and anxiety associated with medical or surgical procedures according to appropriate clinical heuristics |
| CN101070316A (zh) | 1999-04-28 | 2007-11-14 | 萨诺费－阿文蒂斯德国有限公司 | 作为ppar受体配体的二芳基酸衍生物 |
| IL150302A (en) | 2002-01-31 | 2008-07-08 | Naim Menashe | Bicyclic cb2 cannabinoid receptor ligands |
| SE0300010D0 (sv) | 2003-01-07 | 2003-01-07 | Astrazeneca Ab | Novel Compounds |
| ITMI20041033A1 (it) | 2004-05-24 | 2004-08-24 | Neuroscienze S C A R L | Composti farmaceutici |
| WO2005123677A1 (en) | 2004-06-16 | 2005-12-29 | Actelion Pharmaceuticals Ltd | 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents |
| CA2586011C (en) | 2004-07-12 | 2011-07-19 | Cadila Healthcare Limited | Tricyclic pyrazole derivatives as cannabinoid receptor modulators |
| WO2006010379A1 (en) | 2004-07-29 | 2006-02-02 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as immunosuppressive agents |
| FR2875230A1 (fr) | 2004-09-13 | 2006-03-17 | Sanofi Aventis Sa | Derives de pyrazole condense, leur preparation et leur application en therapeutique |
| DE102004054666A1 (de) | 2004-11-12 | 2006-05-18 | Bayer Cropscience Gmbh | Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
| PE20060949A1 (es) | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
| PL1902034T3 (pl) | 2005-06-02 | 2011-09-30 | Glenmark Pharmaceuticals Sa | Nowe ligandy receptorów kanabinoidowych, kompozycja farmaceutyczna je zawierająca oraz proces ich wytwarzania |
| US7597910B2 (en) | 2005-08-20 | 2009-10-06 | Slgm Medical Research Institute | Compositions and methods for treating prostate disorders |
| CA2623803A1 (en) | 2005-09-23 | 2007-03-29 | Janssen Pharmaceutica N.V. | Tetrahydro-cyclopentyl pyrazole cannabinoid modulators |
| SI2081572T1 (sl) | 2006-07-04 | 2010-06-30 | Janssen Pharmaceutica Nv | Benzimidazolni kanabinoidni agonisti ki nosijo substituirano heterociklično skupino |
| EA200900403A1 (ru) | 2006-09-25 | 2009-10-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Соединения, которые модулируют рецептор св2 |
| WO2008063781A2 (en) | 2006-10-12 | 2008-05-29 | Abbott Laboratories | Chemical compounds as cannabinoid receptor ligands |
| WO2008048914A1 (en) | 2006-10-17 | 2008-04-24 | Boehringer Ingelheim International Gmbh | Polycyclic compounds which modulate the cb2 receptor |
| US20080200501A1 (en) | 2006-11-03 | 2008-08-21 | Glenmark Pharmaceuticals S.A. | Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation |
| US8173638B2 (en) | 2006-11-21 | 2012-05-08 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
| US9763894B2 (en) | 2006-12-05 | 2017-09-19 | Virginia Commonwealth University | Inflammation therapy |
| US20090325936A1 (en) | 2006-12-20 | 2009-12-31 | Bilodeau Mark T | Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases |
| US20080161340A1 (en) | 2006-12-20 | 2008-07-03 | Cara Therapeutics, Inc. | Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof |
| WO2008109007A1 (en) | 2007-03-02 | 2008-09-12 | Cara Therapeutics, Inc. | Bridged phenanthridines |
| EP2142531B1 (en) | 2007-03-30 | 2015-07-08 | Janssen Pharmaceutica N.V. | Benzimidazole cannabinoid agonists |
| WO2008157500A1 (en) | 2007-06-17 | 2008-12-24 | Kalypsys, Inc. | Aminoquinazoline cannabinoid receptor modulators for treatment of disease |
| JP5485148B2 (ja) | 2007-06-21 | 2014-05-07 | カラ セラピューティクス インコーポレイテッド | 置換イミダゾ複素環 |
| US8338623B2 (en) | 2007-07-09 | 2012-12-25 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
| US7943658B2 (en) | 2007-07-23 | 2011-05-17 | Bristol-Myers Squibb Company | Indole indane amide compounds useful as CB2 agonists and method |
| EP2203171A2 (en) | 2007-08-21 | 2010-07-07 | Merck Sharp & Dohme Corp. | Cb2 receptor ligands for the treatment of pain |
| UA104010C2 (en) | 2008-12-18 | 2013-12-25 | Эли Лилли Энд Компани | Purine compounds |
| CA2749884C (en) | 2009-01-28 | 2018-01-23 | Cara Therapeutics, Inc. | Bicyclic pyrazolo-heterocycles |
| US7741350B1 (en) | 2009-01-28 | 2010-06-22 | Cara Therapeutics, Inc. | Bicyclic pyrazolo-heterocycles |
| CN102596913B (zh) | 2009-08-28 | 2016-11-09 | 艾尼纳制药公司 | 大麻素受体调节剂 |
| WO2012116278A1 (en) | 2011-02-25 | 2012-08-30 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
| JP6043733B2 (ja) * | 2011-02-25 | 2016-12-14 | アリーナ ファーマシューティカルズ， インコーポレイテッド | カンナビノイド受容体モジュレーター |
| WO2012116277A1 (en) * | 2011-02-25 | 2012-08-30 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
| EA035989B1 (ru) * | 2011-02-25 | 2020-09-09 | Арена Фармасьютикалз, Инк. | Кристаллические формы и способы получения модуляторов каннабиноидного рецептора |
| WO2016085941A1 (en) | 2014-11-25 | 2016-06-02 | Arena Pharmaceuticals, Inc. | Processes for the preparation of cannabinoid receptor modulators |
| US20180252736A1 (en) | 2015-09-01 | 2018-09-06 | Arena Pharmaceuticals, Inc. | Cb2 receptor internalization |
| EA201892280A1 (ru) | 2016-04-10 | 2019-04-30 | Арена Фармасьютикалз, Инк. | Способы лечения селективными агонистами cb-рецептора |
| WO2018208847A1 (en) * | 2017-05-08 | 2018-11-15 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of pain from inflammatory bowel disease |
| MX2019013311A (es) | 2017-05-08 | 2020-08-03 | Arena Pharm Inc | Compuestos y metodos para el tratamiento del dolor visceral. |
| WO2019056123A1 (en) * | 2017-09-22 | 2019-03-28 | Inmed Pharmaceuticals Inc. | TOPICAL FORMULATIONS OF CANNABINOIDS AND THEIR USE IN THE TREATMENT OF PAIN |
| US20240165109A1 (en) * | 2021-03-02 | 2024-05-23 | Arena Pharmaceuticals, Inc. | Methods of Treatment with Selective CB2 Receptor Agonists |
| WO2023059610A1 (en) * | 2021-10-05 | 2023-04-13 | Arena Pharmaceuticals, Inc. | Crystalline forms and processes for the preparation of cannabinoid receptor modulators |
-
2018
- 2018-05-08 MX MX2019013311A patent/MX2019013311A/es unknown
- 2018-05-08 EA EA201992638A patent/EA201992638A1/ru unknown
- 2018-05-08 CA CA3062824A patent/CA3062824A1/en active Pending
- 2018-05-08 JP JP2019561224A patent/JP7247106B2/ja active Active
- 2018-05-08 KR KR1020197036169A patent/KR20200005614A/ko not_active Withdrawn
- 2018-05-08 BR BR112019023214-1A patent/BR112019023214A2/pt not_active Application Discontinuation
- 2018-05-08 MA MA048625A patent/MA48625A/fr unknown
- 2018-05-08 CN CN201880037898.6A patent/CN110709085A/zh active Pending
- 2018-05-08 US US16/611,174 patent/US20200078358A1/en not_active Abandoned
- 2018-05-08 ES ES18727546T patent/ES2956059T3/es active Active
- 2018-05-08 AU AU2018266145A patent/AU2018266145A1/en not_active Abandoned
- 2018-05-08 WO PCT/US2018/031688 patent/WO2018208848A1/en not_active Ceased
- 2018-05-08 EP EP18727546.6A patent/EP3621619B1/en active Active
-
2019
- 2019-11-07 MX MX2022008265A patent/MX2022008265A/es unknown
-
2022
- 2022-06-21 US US17/844,772 patent/US12201633B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2956059T3 (es) | 2023-12-12 |
| EP3621619C0 (en) | 2023-06-28 |
| CA3062824A1 (en) | 2018-11-15 |
| EP3621619A1 (en) | 2020-03-18 |
| US20230033510A1 (en) | 2023-02-02 |
| JP2020518649A (ja) | 2020-06-25 |
| US20200078358A1 (en) | 2020-03-12 |
| WO2018208848A1 (en) | 2018-11-15 |
| MX2019013311A (es) | 2020-08-03 |
| BR112019023214A2 (pt) | 2020-05-26 |
| JP7247106B2 (ja) | 2023-03-28 |
| EA201992638A1 (ru) | 2020-03-18 |
| EP3621619B1 (en) | 2023-06-28 |
| CN110709085A (zh) | 2020-01-17 |
| MX2022008265A (es) | 2022-08-04 |
| AU2018266145A1 (en) | 2019-11-28 |
| KR20200005614A (ko) | 2020-01-15 |
| US12201633B2 (en) | 2025-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3813808A4 (en) | Methods of treating substance abuse | |
| MA46102A (fr) | Composés de tétracycline et méthodes de traitement | |
| EP3613073A4 (en) | DIE TREATMENT | |
| EP3645121A4 (en) | METHOD OF TREATMENT FOR HUNTINGTON'S MORBUS | |
| EP3370721A4 (en) | TREATMENT OF OSTEOARTHRITIS | |
| EP3589659A4 (en) | COMPOUNDS AND USES FOR TREATMENT OF CANCER | |
| EP3634442A4 (en) | METHODS OF TREATMENT AND PREVENTION OF DISEASES | |
| EP3658139A4 (en) | Methods for treating liver diseases | |
| EP3946345A4 (en) | METHODS OF TREATMENT OF NEUROPATHIC PAIN | |
| EP3706737A4 (en) | ASH11 INHIBITORS AND METHOD OF TREATING THEREOF | |
| MA48730A (fr) | Compositions et méthodes de traitement de synucléinopathies | |
| MA53329A (fr) | Méthodes de traitement de l'épilepsie | |
| EP3630101A4 (en) | METHODS OF TREATMENT OF FIBROTIC DISEASES | |
| EP3606531A4 (en) | METHOD OF TREATMENT OF CANCER | |
| EP3634422A4 (en) | Methods of treating leukodystrophies | |
| EP3745862A4 (en) | METHOD OF TREATMENT OF FIBROTIC DISEASES | |
| EP3713583A4 (en) | METHODS AND COMPOSITIONS FOR TREATMENT OF THE SKIN | |
| MA51678A (fr) | Méthodes de traitement de l'amyotrophie musculaire | |
| EP3313417A4 (en) | METHOD FOR TREATING AUTOIMMUNE AND ALLOIMMUNE DISEASES | |
| EP3383857A4 (en) | COMPOUNDS AND METHOD FOR THE TREATMENT OF BACTERIAL INFECTIONS | |
| IL270900A (en) | Treatment of cutaneous disorders | |
| MA46353A (fr) | Méthodes de traitement de l'infertilité féminine | |
| EP3852816A4 (en) | METHODS OF TREATMENT OF CANCER | |
| EP3458062A4 (en) | Treatment of pain | |
| EP3873528A4 (en) | Rasopathy treatment |